ERBB2 and breast carcinoma: In breast cancer, we used SCMGENE [20] as implemented in the R/Bioconductor genefu package [22] to assign patients to one of four molecular subtypes: ER+/HER2− low proliferation, ER+/HER2− high proliferation, ER−/HER2− and HER2+.